Acambis will receive from Sanofi Pasteur an upfront payment, a milestone payment on licensure of the vaccine in India and royalties on sales in these territories. Bharat Biotech has made a significant contribution towards the development of ChimeriVax-JE (Japanese encephalitis) and Acambis has agreed to compensate Bharat Biotech. As with the existing agreement, Acambis will supply bulk ChimeriVax-JE vaccine to Sanofi Pasteur from its Canton, Massachusetts facility.
Ian Garland, CEO of Acambis, said: “This extended agreement will enable both Acambis and Sanofi Pasteur to benefit from a more co-ordinated approach in the JE endemic region. ChimeriVaxTM-JE is an important vaccine for a devastating disease and we are keen to progress towards licensure as quickly as possible.”